Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Type 3 Choroidal Neovascularization
NCT02320474Phase 4Completed
- Sponsor
- CHU de Poitiers
- Start
- Nov 2014
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in choroidal neovascularization (CNV), sponsored by CHU de Poitiers. Started Nov 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02320474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320474.